Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients
- PMID: 18990163
- DOI: 10.1111/j.1464-410X.2008.08003.x
Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients
Erratum in
- BJU Int. 2009 Aug;104(4):574. Karakiewizc, Pierre [corrected to Karakiewicz, Pierre]
Abstract
Objective: To assess whether tumour architecture can help to refine the prognosis of patients treated with nephroureterectomy (NU) for urothelial carcinoma (UC) of the upper urinary tract (UT), as the prognostic value of tumour architecture (papillary vs sessile) in UTUC remains elusive.
Patients and methods: The study included 1363 patients with UTUC and treated with radical NU at 12 centres worldwide. All slides were re-reviewed according to strict criteria by genitourinary pathologists who were unaware of the findings of the original pathology slides and clinical outcomes. Gross tumour architecture was categorized as sessile vs papillary.
Results: Papillary growth was identified in 983 patients (72.2%) and sessile growth in 380 (27.8%). The sessile growth pattern was associated with higher tumour grade, more advanced stage, lymphovascular invasion, and metastasis to lymph nodes (all P < 0.001). In multivariable Cox regression analyses that adjusted for the effects of pathological stage, grade and lymph node status, tumour architecture (sessile or papillary) was an independent predictor of cancer recurrence (hazard ratio 1.5, P = 0.002) and cancer-specific mortality (1.6, P = 0.001). Adding tumour architecture increased the predictive accuracy of a model that comprised pathological stage, grade and lymph node status for predicting cancer recurrence and cancer-specific death by a minimal but statistically significant margin (gain in predictive accuracy 1% and 0.5%, both P < 0.001).
Conclusion: The tumour architecture of UTUC is associated with established features of biologically aggressive disease, and more importantly, with prognosis after radical NU. Including tumour architecture in predictive models for disease progression should be considered, aiming to identify patients who might benefit from early systemic therapeutic intervention.
Similar articles
-
Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density.BJU Int. 2009 Feb;103(3):302-6. doi: 10.1111/j.1464-410X.2008.07988.x. Epub 2008 Oct 16. BJU Int. 2009. PMID: 18990164
-
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration.Cancer. 2009 Mar 15;115(6):1224-33. doi: 10.1002/cncr.24135. Cancer. 2009. PMID: 19156917
-
Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma.Urol Oncol. 2012 Sep;30(5):666-72. doi: 10.1016/j.urolonc.2010.07.010. Epub 2010 Oct 8. Urol Oncol. 2012. PMID: 20933445
-
Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer.Eur Urol. 2011 Oct;60(4):776-83. doi: 10.1016/j.eururo.2011.07.009. Epub 2011 Jul 14. Eur Urol. 2011. PMID: 21798659 Review.
-
Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments.BJU Int. 2007 Jul;100(1):11-6. doi: 10.1111/j.1464-410X.2007.06841.x. Epub 2007 Apr 8. BJU Int. 2007. PMID: 17428248 Review.
Cited by
-
Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma.Turk J Urol. 2021 Feb;47(Supp. 1):S33-S44. doi: 10.5152/tud.2020.20392. Epub 2020 Oct 9. Turk J Urol. 2021. PMID: 33052841 Free PMC article. Review.
-
Perioperative chemotherapy for upper tract urothelial cancer.Nat Rev Urol. 2012 Apr 10;9(5):266-73. doi: 10.1038/nrurol.2012.57. Nat Rev Urol. 2012. PMID: 22487872 Review.
-
The prognostic value of tumor architecture in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: A systematic review and meta-analysis.Medicine (Baltimore). 2020 Sep 11;99(37):e22176. doi: 10.1097/MD.0000000000022176. Medicine (Baltimore). 2020. PMID: 32925787 Free PMC article.
-
Oncologic outcomes of radical nephroureterectomy (RNU).Transl Androl Urol. 2020 Aug;9(4):1841-1852. doi: 10.21037/tau.2019.12.29. Transl Androl Urol. 2020. PMID: 32944548 Free PMC article. Review.
-
P21 and p27 Immunoexpression in Upper Urinary Tract Urothelial Carcinomas.Pathol Oncol Res. 2016 Oct;22(4):839-45. doi: 10.1007/s12253-016-0075-4. Epub 2016 May 24. Pathol Oncol Res. 2016. PMID: 27222134
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials